{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:44:23Z","timestamp":1793573063312,"version":"4.5.0"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2023,12,15]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Scleritis may be idiopathic or caused by trauma, infections, or an immune-mediated disease (IMD). Our study aimed to understand the relationship between scleritis and IMD, including presenting characteristics, serologies, and treatment course. Understanding these associations may allow clinicians to risk-stratify patients and predict their clinical and treatment course.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective chart review of 341 patients with scleritis seen at a tertiary care center between January 1, 2005, and December 31, 2020. Demographics, scleritis characteristics, treatment response, recurrence, and serologic data were compared among patients with idiopathic and IMD-associated scleritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among patients with scleritis seen, 145 patients (43%) had an associated IMD, most commonly rheumatoid arthritis (RA; 39%), vasculitis (21%), or inflammatory bowel disease (14%). In most cases, the IMD diagnosis predated the scleritis presentation (63%), though vasculitis cases were more likely to develop during or after scleritis episodes. There were no significant differences in demographics or treatment failures among patients with scleritis with and without associated IMDs. Patients with IMDs were more likely to have a recurrence of scleritis (62% vs 49%,<jats:italic>P<\/jats:italic>= 0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>At our ophthalmology center, 43% of patients with scleritis had an associated IMD, and most patients with an IMD were symptomatic from this disease prior to scleritis presentation. RA was the most commonly associated condition and typically predated the scleritis, whereas vasculitis was more likely diagnosed during or after the scleritis episode. Scleritis among patients with IMD is more likely to recur compared to scleritis that is idiopathic.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-0788","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:25:14Z","timestamp":1706793914000},"page":"825-830","source":"Crossref","is-referenced-by-count":6,"title":["Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6356-1145","authenticated-orcid":false,"given":"Tessalyn","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriah","family":"Gottman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toan","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-2183","authenticated-orcid":false,"given":"Daniela","family":"Ghetie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2024080105251905000_51.8.825.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.06.006"},{"key":"2024080105251905000_51.8.825.2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.survophthal.2016.06.002","article-title":"Treatment and management of scleral disorders","volume":"61","author":"Daniel Diaz","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"2024080105251905000_51.8.825.3","doi-asserted-by":"crossref","first-page":"108078","DOI":"10.1016\/j.exer.2020.108078","article-title":"Current insights in the pathogenesis of scleritis","volume":"197","author":"Vergouwen","year":"2020","journal-title":"Exp Eye Res"},{"key":"2024080105251905000_51.8.825.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2005.04.001"},{"key":"2024080105251905000_51.8.825.5","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2010.24.6.331"},{"key":"2024080105251905000_51.8.825.6","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1544372"},{"key":"2024080105251905000_51.8.825.7","first-page":"1215","article-title":"Clinical features and visual outcomes of scleritis patients presented to tertiary care eye centers in Saudi Arabia","volume":"8","author":"Al Barqi","year":"2015","journal-title":"Int J Ophthalmol"},{"key":"2024080105251905000_51.8.825.8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/09273948.2022.2042317","article-title":"Clinical profile, systemic association, treatment and visual outcome of patients with scleritis in an eye care center in Mexico City","volume":"31","author":"Suarez Avellaneda","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"2024080105251905000_51.8.825.9","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/jcm12051969","article-title":"Systemic disease associations in a cohort of Hispanic patients with scleritis","volume":"12","author":"Arruza","year":"2023","journal-title":"J Clin Med"},{"key":"2024080105251905000_51.8.825.10","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000394"},{"key":"2024080105251905000_51.8.825.11","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1080\/09273948.2021.1942497","article-title":"Patterns of non-infectious scleritis across a tertiary eye care network using the indigenously developed electronic medical record system\u2013eyeSmart","volume":"30","author":"Murthy","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"2024080105251905000_51.8.825.12","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2015.1005240"},{"key":"2024080105251905000_51.8.825.13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/09273948.2016.1249376","article-title":"Ocular autoimmune systemic inflammatory infectious study (OASIS) \u2013 report 1: epidemiology and classification","volume":"26","author":"Chen","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"2024080105251905000_51.8.825.14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1590\/S0004-27492011000600004","article-title":"Comparative study of ophthalmological and serological manifestations and the therapeutic response of patients with isolated scleritis and scleritis associated with systemic diseases","volume":"74","author":"Sousa","year":"2011","journal-title":"Arq Bras Oftalmol"},{"key":"2024080105251905000_51.8.825.15","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s00417-022-05754-y","article-title":"Clinical patterns and risk factors in scleritis: a multicentric study in Colombia","volume":"260","author":"de-la-Torre","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2024080105251905000_51.8.825.16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/ICO.0b013e3181ac9fad","article-title":"Clinical features, prognosis, and treatment results of patients with scleritis from 2 tertiary eye care centers in Turkey","volume":"29","author":"Erkanli","year":"2010","journal-title":"Cornea"},{"key":"2024080105251905000_51.8.825.17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/09273948.2013.854394","article-title":"Clinical characteristics of scleritis and episcleritis: results from the Pacific Ocular Inflammation Study","volume":"22","author":"Homayounfar","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"2024080105251905000_51.8.825.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00710-8"},{"key":"2024080105251905000_51.8.825.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90543-2"},{"key":"2024080105251905000_51.8.825.20","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13761"},{"key":"2024080105251905000_51.8.825.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.08.005"},{"key":"2024080105251905000_51.8.825.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.04.043"},{"key":"2024080105251905000_51.8.825.23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/09273948.2016.1241282","article-title":"Clinical features and complications of scleritis in Chinese patients","volume":"26","author":"Yang","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"2024080105251905000_51.8.825.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-019-00674-7"},{"key":"2024080105251905000_51.8.825.25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12886-020-01769-3","article-title":"Health system wide \u201cbig data\u201d analysis of rheumatologic conditions and scleritis","volume":"21","author":"Berkenstock","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"2024080105251905000_51.8.825.26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/art.41709","article-title":"Epidemiology of scleritis in the United Kingdom from 1997 to 2018: population-based analysis of 11 million patients and association between scleritis and infectious and immune-mediated inflammatory disease","volume":"73","author":"Braithwaite","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024080105251905000_51.8.825.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.07.021"},{"key":"2024080105251905000_51.8.825.28","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.126.5.651"},{"key":"2024080105251905000_51.8.825.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.09.024"},{"key":"2024080105251905000_51.8.825.30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/09273948.2022.2079532","article-title":"Combined ophthalmology and rheumatology evaluation in systemic autoimmune diseases with ocular involvement: a third level reference center in Mexico","volume":"31","author":"Baquero-Ospina","year":"2023","journal-title":"Ocul Immunol Inflam"},{"key":"2024080105251905000_51.8.825.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170437"},{"key":"2024080105251905000_51.8.825.32","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.171744"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-0788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:37:57Z","timestamp":1722515877000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-0788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.3899\/jrheum.2023-0788"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-0788","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}